These differences could be related to differences in cell and/or tissue context, since we consistently observed that dasatinib reduced the phosphorylation levels of SRC and also AKT whilst increasing endogenous Sox2 levels in HNSCC cells and also Sox2/Oct4 reporter activity. This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.